skin elements
enhancing health + wellness naturally

1255A Hay Street, West Perth
Western Australia, 6005
P +61 (8) 6311 1900

www.sknlife.com.au
www.skinelementslimited.com
info@skinelementslimited.com

For personal use only

10 November2026

Dear Shareholders

Addendum to the Notice of the 2026 Annual General Meeting – Skin Elements Limited

Skin Elements Limited (SKN) advises of changes to the resolutions of the Notice of Meeting for the 2026 Annual General Meeting.

Any proxy appointment or vote you previously lodged will not have instructions on the new resolutions.

If you wish to vote on the new resolutions, please lodge a new proxy using the instructions below

In accordance with the Corporations Amendments (Meetings and Documents) Act 2022 which came into effect on 1 April 2022, the Company will not be dispatching physical copies of this Addendum to the Notice of Meeting (Notice). Instead, the Notice is being made available to shareholders electronically and can be viewed and downloaded from the online ASX platform at https://www.asx.com.au/markets/company/SKN, or the Company's website at https://skinelementslimited.com/announcements/ .

The Company strongly encourages Shareholders to vote by voting online at https://au.investorcentre.mpms.mufg.com/ or by lodging the associated proxy form to the Notice. Shareholders will be able to vote at the Meeting by either lodging a Proxy Form prior to the Meeting, or by poll during the Meeting.

Proxy Forms can be lodged as noted below. Instructions on how to complete the Proxy Form are set out in the NOM.

A copy of your new personalised proxy form is enclosed for your convenience. Your proxy voting instructions must be received by 12.00PM (AWST) on 28th November 2026, being not less than 48 hours before the commencement of the Meeting.

ONLINE	https://au.investorcentre.mpms.mufg.com/
BY MAIL	**Skin Elements Limited**
	C/- MUFG Corporate Markets (AU) Limited
	Locked Bag A14
	Sydney South NSW 1235 Australia
BY HAND	**MUFG Corporate Markets (AU) Limited**
	Parramatta Square, Level 22, Tower 6,
	10 Darcy Street, Parramatta NSW 2150

ALL ENQUIRIES TO: **Telephone: +61 1300 554 474**

LATEST LODGEMENT DATE: **12.00PM (AWST) Saturday, 28th November 2026**

The NOM should be read in its entirety. If you are in doubt as to how to vote, the Company encourages Shareholders to seek advice from their accountant, solicitor or other professional advisor prior to voting. If you have any difficulties in obtaining a copy of the NOM, please contact Stuart Usher by email (stuart@skinelementslimited.com) or by telephone on (08) 6311 1900.

For and on behalf of the Board.

Yours faithfully

SKIN ELEMENTS LIMITED



Stuart Usher

Company Secretary

For personal use only

For personal use only

Addendum to Notice of Annual General Meeting

Skin Elements Limited (ACN 608 047 794) (the **Company**) hereby gives notice to Shareholders that, in relation to the Notice of Annual General Meeting dated 29 October 2026 (**Notice**) in respect of the Annual General Meeting of the Company to be held at the Boorloo Meeting Room, Ground Floor, 108 St Georges Terrace, Perth WA 6000 on Monday, 30 November 2026 at 12:00pm (AWST) (**Meeting**), the directors of the Company (**Directors**) have resolved to amend the Notice by this addendum to the Notice (**Addendum**) for the purposes set out below.

In the same manner as the Notice was dispatched to Shareholders and in accordance with the *Corporations Act 2001* (Cth) (**Corporations Act**), the Company will not be dispatching hard copies of the Addendum unless the Shareholder has made a valid election to receive documents from the Company in hard copy. The Addendum can be viewed and downloaded from the Company's website at https://skinelementslimited.com/announcements/ or on the ASX platform at https://www.asx.com.au/markets/company/SKN.

Summary of Changes to the Notice

By way of summary, the changes to the Notice are as follows:

(a) inclusion of additional Resolutions 11(a), 11(b), 12, 13 and 14 (**Additional Resolutions**) in respect of a recent Placement conducted by the Company; and

(b) replacement of Section 13 of the Explanatory Memorandum, and the inclusion of Schedule 3 (in respect of Resolution 10) relating to the renewal of the Company's Listing Rule 7.1A capacity to reflect issues under the Placement.

This Addendum is supplemental to the original Notice and should be read in conjunction with the Notice. Save for the amendments set out below, the Notice remains unchanged.

The numbering used in this Addendum is a continuation of the numbering used in the Notice and the Explanatory Memorandum. Unless otherwise defined in this Addendum, the defined terms used in this Addendum are as defined in the Notice.

The Company has sought legal advice confirming the Additional Resolutions will be legally valid and binding on the Company if passed by Shareholders at the Meeting.

This Addendum should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their suitably qualified professional advisors prior to voting. Should you wish to discuss the matters set out in this Addendum, please do not hesitate to contact Stuart Usher by email (stuart@skinelementslimited.com) or by telephone on (08) 6311 1900.

For personal use only

Proxy Forms

Annexed to this Addendum is a replacement Proxy Form (**Replacement Proxy Form**). To ensure clarity of voting instructions by Shareholders on Resolutions 1 – 10 in the Notice and Additional Resolutions to be considered at the Meeting, Shareholders are advised that:

(a) If you have already completed and returned the Proxy Form annexed with the Notice (**Original Proxy Form**) and you wish to change your original vote for Resolutions 1 – 10 or cast votes for the Additional Resolutions (11(a), 11(b), 12, 13 and 14), **you must complete and return the Replacement Proxy Form.**

(b) If you have already completed and returned the Original Proxy Form and **you do not wish to change your original vote for Resolutions 1 – 10 or vote on the Additional Resolutions, you do not need to take any action** as your earlier submitted Original Proxy Form will be accepted by the Company for Resolutions 1 – 10 unless you submit a Replacement Proxy Form. For the avoidance of doubt, the Company notes that if you do not lodge a Replacement Proxy Form, **you will not have cast a vote on the Additional Resolutions**.

(c) If you have not yet completed and returned a Proxy Form and you wish to vote on Resolutions 1 – 10 in the Notice and the Additional Resolutions included in the Addendum, **please complete and return the Replacement Proxy Form.**

Proxies may be lodged using any of the following methods:

Online: https://au.investorcentre.mpms.mufg.com/

By mail: Skin Elements Limited

C/- MUFG Corporate Markets (AU) Limited

Locked Bag A14 Sydney South NSW 1235 Australia

By hand: MUFG Corporate Markets (AU) Limited

Parramatta Square, Level 22, Tower 6,

10 Darcy Street, Parramatta NSW 2150

The last Proxy Form you lodge before the latest time for receipt of Proxy Forms (being not later than 48 hours before the commencement of the Meeting) will be taken to be your Proxy Form for voting on items of business at the Meeting.

Voting Instructions and Chair's voting intentions

If the Chair is appointed as your proxy and the Chair is not directed how to vote, you are authorising the Chair to cast your undirected vote on all proposed resolutions.

If a member of the Company's Key Management Personnel, or a Closely Related Party of such member, is appointed as your proxy, they will not be able to vote your proxy on Resolution 1 unless you have directed them how to vote.

If you intend to appoint a member of the Company's Key Management Personnel, or a Closely Related Party of such member, or the Chair, as your proxy, you are encouraged to direct them how to vote on Resolution 1 by marking "For", "Against" or "Abstain" for each of those resolutions.

Additional Resolutions

Resolutions 11(a), 11(b), 12, 13 and 14 are included in the Notice as follows:

7. RESOLUTIONS 11(A) AND 11(B) – RATIFICATION OF PRIOR ISSUE OF OCTOBER PLACEMENT SHARES

To consider and, if thought fit, to pass with or without amendment, as **ordinary resolutions** the following:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders approve and ratify the prior issue of:

(a) 59,821,091 October Placement Shares issued under the Company's Listing Rule 7.1 capacity;

(b) 258,360,727 October Placement Shares issued under the Company's Listing Rule 7.1A capacity,

on the terms and conditions set out in the Explanatory Memorandum."

Voting Exclusion Statement

The Company will disregard any votes cast in favour of the Resolutions by or on behalf of:

(a) a person who participated in the issue or is a counterparty to the agreement being approved (namely, the October Placement Participants (and/or their respective nominees)); or

(b) an Associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolutions by:

(a) a person as proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with directions given to the proxy or attorney to vote on the Resolutions in that way; or

(b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with a direction given to the Chair to vote on the Resolutions as the Chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolutions; and

(ii) the holder votes on the Resolutions in accordance with directions given by the beneficiary to the holder to vote in that way.

8. RESOLUTION 12 – RATIFICATION OF PRIOR ISSUE OF OCTOBER LEAD MANAGER SHARES IN LIEU OF FEES

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution**, the following:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders approve and ratify the prior issue of 19,090,909 October Lead Manager Shares issued under the Company's Listing Rule 7.1 capacity, on the terms and conditions set out in the Explanatory Memorandum"

Voting Exclusion Statement

The Company will disregard any votes cast in favour of the Resolution by or on behalf of:

(a) a person who participated in the issue or is a counterparty to the agreement being approved (namely, the October Lead Manager, Pheonix Global Investments Pty Ltd (and/or its nominees)); or

(b) an Associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolutions by:

(a) a person as proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with directions given to the proxy or attorney to vote on the Resolutions in that way; or

(b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with a direction given to the Chair to vote on the Resolutions as the Chair decides; or

For personal use only

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolutions; and

(ii) the holder votes on the Resolutions in accordance with directions given by the beneficiary to the holder to vote in that way.

9. RESOLUTION 13 – APPROVAL TO ISSUE OCTOBER PLACEMENT OPTIONS

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution**, the following:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue up to 318,181,818 October Placement Options on the terms and conditions set out in the Explanatory Memorandum"

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

(a) a person (or persons) who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) (namely, the October Placement Participants (and/or their respective nominees)); or

(b) an Associate of that person or those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or

(b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and

(ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

10. RESOLUTION 14 – APPROVAL TO ISSUE OCTOBER LEAD MANAGER OPTIONS

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution**, the following:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue up to 19,090,909 October Lead Manager Options on the terms and conditions set out in the Explanatory Memorandum"

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

(a) a person (or persons) who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) (namely, the October Lead Manager, Pheonix Global Investments Pty Ltd (and/or its nominees)); or

(b) an Associate of that person or those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

(a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or

(b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

For personal use only


(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and

(ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Dated 10 November 2026

BY ORDER OF THE BOARD



Stuart Usher
Company Secretary
Skin Elements Limited

For personal use only

For personal use only

Skin Elements Limited
(ACN 608 047 794)
(Company)

Addendum to the Explanatory Memorandum

The Company hereby gives notice of the amendment of the Explanatory Memorandum in the Notice as set out in this Addendum. The amendment set out in this Addendum replaces the text included in the Explanatory Memorandum with respect to Resolution 10 of the Explanatory Memorandum, and new Sections 14 – 17 and Schedules 2 and Schedule 3 of the Explanatory Memorandum in respect of the Additional Resolutions are added to the Explanatory Memorandum in relation to the Notice.

The Explanatory Memorandum in the Notice is supplemented with the following information as follows:

13 RESOLUTION 10 – APPROVAL OF 10% FACILITY

13.1 Background

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

Listing Rule 7.1A enables eligible entities to seek shareholder approval by way of a special resolution to issue Equity Securities up to 10% of its issued share capital through placements over a 12 month period after the annual general meeting (**10% Placement Facility**). The 10% Placement Facility is in addition to the Company's 15% placement capacity under Listing Rule 7.1.

The ability to issue Equity Securities under the 10% Placement Facility is subject to Shareholder approval by way of a special resolution at an annual general meeting.

An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of $300 million or less. The Company is an eligible entity as it is not included in the S&P/ASX 300 Index and has a market capitalisation, as at 9 November 2026 of $7.69 million.

The Company is seeking Shareholder approval to provide the Company with the ability to issue Equity Securities under the 10% Placement Facility during the 10% Placement Period (refer to below). The number of Equity Securities to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer to below).

The Company is seeking a mandate to issue securities under the 10% Placement Facility to enable the Company to pursue its growth strategy with the flexibility to act quickly as potential business opportunities arise.

Resolution 10 is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

The exact number of equity securities that the Company may issue under the 10% Placement Facility will be determined in accordance with the following formula:

(A x D) – E

Where:

"A" is the number of shares on issue 12 months before the date of issue or agreement:

(i) plus, the number of fully paid ordinary securities issued in the relevant period under an exception in Listing Rule 7.2 other than exception 9, 16 or 17;

(ii) plus, the number of fully paid ordinary securities issued in the relevant period on the conversion of convertible securities within Listing Rule 7.2 exception 9 where:

(A) the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or

(B) the issue of, or agreement to issue the convertible securities was approved, or taken under the Listing Rules to have been approved under Listing Rule 7.1 or Listing Rule 7.4;

(iii) plus the number of fully paid ordinary securities issued in the relevant period under an agreement to issue securities within Listing Rule 7.2 exception 16 where:

(A) the agreement was entered into before the commencement of the relevant period; or

(B) the agreement or issue was approved, or taken under these rules to have been approved under Listing Rule 7.1 or Listing Rule 7.4;

(iv) plus, the number of any other fully paid ordinary securities issued in the relevant period with approval under Listing Rule 7.1 or Listing Rule 7.1A;

(v) plus, the number of partly paid ordinary securities that became fully paid in the relevant period; and

(vi) less the number of fully paid ordinary securities cancelled in the relevant period.

Note that variable "A" has the same meaning in Listing Rule 7.1 when calculating an entity's 15% placement capacity.

"D" is 10%

"E" is the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of issue or agreement to issue that are not issued with the approval of shareholders under Listing Rule 7.1 or 7.4.

"**relevant period**" means the 12 month period immediately preceding the date of the issue or agreement.

If Resolution 10 is passed, the Company will be able to issue Equity Securities under Listing Rule 7.1A up to 10% of its issued share capital over a 12 month period after the annual general meeting, in addition to the Company's 15% placement capacity under Listing Rule 7.1.

For personal use only

If Resolution 10 is not passed, the Company will not be able to access the 10% Placement Facility to issue Equity Securities without Shareholder approval provided for in Listing Rule 7.1A and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval under Listing Rule 7.1.

13.2 Listing Rule 7.1A

In compliance with the information requirements of Listing Rule 7.3A, Shareholders are advised of the following information:

(a) **Issue period**

If Shareholders approve Resolution 10, the Company will have a mandate to issue equity securities under the 10% Placement Facility under Listing Rule 7.1A from the date of this Meeting until the first to occur of the following:

(i) the date that is 12 months after the date of this Meeting;

(ii) the time and date of the Company's next annual general meeting; and

(iii) the time and date of approval by Shareholders of any transaction under Listing Rule 11.1.2 (a significant change in the nature or scale of activities) or Listing Rule 11.2 (disposal of the main undertaking),

(the **10% Placement Period**).

The Company will only issue the Equity Securities during the 10% Placement Period. The approval under Resolution 10 for the issue of the Equity Securities will cease to be valid in the event that Shareholders approve a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking).

(b) **Minimum issue price**

Any Equity Securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of equity securities of the Company.

The Company, as at the date of this Notice, has on issue one class of quoted Equity Securities being Shares.

The issue price of Equity Securities issued under Listing Rule 7.1A must be not less than 75% of the VWAP of Equity Securities in the same class calculated over the 15 Trading Days on which trades in that class were recorded immediately before:

(i) the date on which the price at which the Equity Securities are to be issued is agreed; or

(ii) if the Equity Securities are not issued within 10 Trading Days of the date in paragraph (i) above, the date on which the Equity Securities are issued.

(c) **Purpose of issues**

The Company may only issue the Equity Securities for cash consideration. In such circumstances, the Company intends to use the funds raised towards the acquisition of new assets or investments (including expenses associated with such acquisition) and/or general working capital.

For personal use only

The Company will provide further information at the time of issue of any equity securities under the 10% Placement Facility in compliance with its disclosure obligations under Listing Rules 7.1A.4 and 3.10.3.

(d) **Dilution**

As at the date of this Notice, the Company has on issue 3,846,606,842 Shares. Accordingly, if Shareholders approve this Resolution, the Company will have the capacity to issue up to approximately 384,660,684 Equity Securities under the 10% Placement Facility in accordance with Listing Rule 7.1A.

If this Resolution is approved by the Shareholders and the Company issues equity securities under the 10% Placement Facility, the existing Shareholders' voting power in the Company will be diluted as shown in the below table. There is a risk that:

(i) the market price for the Company's Equity Securities may be significantly lower on the date of the issue of the Equity Securities than on the date of the Meeting; and

(ii) the Equity Securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date of the Equity Securities,

which may have an effect on the amount of funds raised by the issue of the Equity Securities.

The below table shows the dilution of existing Shareholders on the basis of the current market price of Shares and the current number of ordinary securities for variable 'A' calculated in accordance with the formula in Listing Rule 7.1A(2) as at 9 November 2026.

The table also shows:

(iii) two examples where variable 'A' has increased, by 50% and 100%. Variable 'A' is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and

(iv) two examples of where the issue price of ordinary securities has decreased by 50% and increased by 50% as against the current market price as at 9 November 2026.

For personal use only

Variable "A" in Listing Rule 7.1A.2	Shares Issued - 10% Voting Dilution	Dilution		
		$0.0010 50% decrease in Issue Price	$0.002 Issue Price	$0.003 50% increase in Issue Price
		Funds Raised		
Current Variable "A" 3,846,606,842	384,660,684	$384,661	$769,321	$1,153,982
50% increase in current Variable "A" 5,769,910,263	$576,991,026	$576,991	$1,153,982	$1,730,973
100% increase in current Variable "A" 7,693,213,684	$769,321,368	$769,321	$1,538,643	$2,307,964

The table has been prepared on the following assumptions:

(i) The Company issues the maximum number of Equity Securities available under the 10% Placement Facility.

(ii) The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.

(iii) The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder's holding at the date of the Meeting.

(iv) The table shows only the effect of issues of Equity Securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1.

(v) The issue of Equity Securities under the 10% Placement Facility consists only of Shares.

(vi) The issue price is $0.002 being the closing price of the Shares on ASX on 9 November 2026.

(e) **Allocation policy**

The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of the subscribers of Equity Securities will be determined on a case-by-case basis having regard to the factors including but not limited to the following:

(i) the methods of raising funds that are available to the Company, including but not limited to, rights issue or other issue in which existing security holders can participate;

(ii) the effect of the issue of the Equity Securities on the control of the Company;

(iii) the financial situation and solvency of the Company; and

(iv) advice from corporate, financial and broking advisers (if applicable).

For personal use only

The subscribers under the 10% Placement Facility have not been determined as at the date of this Notice but may include existing substantial Shareholders and/or new Shareholders who are not a related party or an associate of a related party of the Company.

(f) **Previous issues of Equity Securities under Listing Rule 7.1A**

The Company has previously obtained Shareholder approval under Listing Rule 7.1A at its annual general meeting held on 28 November 2025. In the 12 months preceding the date of this Meeting, and as at the date of this Notice, the Company issued a total of 258,360,727 Shares under Listing Rule 7.1A.2, representing approximately 21% of the total number of Equity Securities on issue at the 28 November 2025 Annual General Meeting. Further details of the Equity Securities issued in the preceding 12-month period pursuant to Listing Rule 7.3A6 are set out in Schedule 3.

(g) **Voting exclusion statement**

There is no voting exclusion statement for this Resolution. At the date of this Notice, the Company has not approached any particular existing security holder or an identifiable class of existing security holders to participate in the issue of the Equity Securities using the Additional 10% Placement Facility. Accordingly, the proposed persons to whom any Equity Securities may be issued under the Additional 10% Placement Facility are not as yet known or identified. No existing Shareholder's votes will therefore be excluded from voting on Resolution 10.

14 RESOLUTIONS 11(A) AND 11(B) – RATIFICATION OF PRIOR ISSUE OF OCTOBER PLACEMENT SHARES

14.1 Background

On 27 October 2026, the Company announced that it received firm commitments to raise $700,000 (before costs) through a placement of 318,181,818 fully paid ordinary shares (**October Placement Shares**) at an issue price of $0.0022 per October Placement Share, together with one (1) free-attaching Option for every one (1) October Placement Share subscribed for and issued, exercisable at $0.004 and expiring three years from the date of issue (**October Placement Option**) (**October Placement**), as follows:

(a) 59,821,091 October Placement Shares were issued under the Company's existing Listing Rule 7.1 capacity on 9 November 2026 (the subject of Resolution 11(a));

(b) 258,360,727 October Placement Shares were issued under the Company's existing Listing Rule 7.1A capacity on 9 November 2026 (the subject of Resolution 11(b)); and

(c) 318,181,818 October Placement Options to be issued subject to Shareholder approval (the subject of Resolution 13).

Pheonix Global Investments Pty Ltd (**October Lead Manager**) acted as lead manager to the October Placement pursuant to a lead manager mandate (**October Lead Manager Mandate**).

Funds raised from the October Placement will provide the Company with a strengthened balance sheet and additional working capital to support the advancement and commercialisation of the Company's existing product programs.

14.2 Listing Rules 7.1, 7.1A and 7.4

Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more equity securities during any 12-month period than that amount which

For personal use only

represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12-month period.

Listing Rule 7.1A enables eligible entities to issue equity securities up to 10% of its issued share capital through placements over a 12 month period after the annual general meeting at which shareholders approve the 10% placement facility. The 10% placement facility is in addition to the Company's 15% placement capacity under Listing Rule 7.1.

The issue of the October Placement Shares does not fit within the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 25% limit in Listing Rules 7.1 and 7.1A, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rule 7.1 and 7.1A for the 12 month period following the date of issue of the October Placement Shares.

Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the company's capacity to issue further equity securities without shareholder approval under that rule.

The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval for such issues under Listing Rule 7.1. To this end, Resolutions 11(a) and 11(b) seek Shareholder approval for the ratification of the issue of the October Placement Shares under and for the purpose of Listing Rule 7.4.

14.3 Technical information required by Listing Rule 14.1A

If Resolutions 11(a) and 11(b) are passed, the issue of the October Placement Shares will be excluded in calculating the Company's 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date.

If Resolutions 11(a) and 11(b) are not passed, the October Placement Shares will be included in calculating the Company's 25% limit in Listing Rules 7.1 and 7.1A, effectively decreasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date.

14.4 Technical information required by Listing Rule 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in relation to Resolutions 11(a) and 11(b):

(a) the October Placement Shares were issued to sophisticated and professional investors who are clients of the October Lead Manager (**October Placement Participants**) (and/or their respective nominees). The October Placement Participants were identified through a book build process, which involved the October Lead Manager seeking expressions of interest to participate in the October Placement from non-related parties of the Company;

(b) in accordance with paragraph 7.4 of Guidance Note 21, the Company confirms that none of the October Placement Participants are:

(i) related parties of the Company, members of the Company's Key Management Personnel, substantial holders of the Company, advisers of the Company or an associate of any of these parties; and

(ii) were issued more than 1% of the issued capital of the Company;

For personal use only

(c) a total of 318,181,818 October Placement Shares were issued as follows:

(i) 59,821,091 October Placement Shares were issued pursuant to the Company's placement capacity under Listing Rule 7.1 (being the subject of Resolution 11(a)); and

(ii) 258,360,727 October Placement Shares were issued pursuant to the Company's placement capacity under Listing Rule 7.1A (being the subject of Resolution 11(b));

(d) the October Placement Shares issued were all fully paid ordinary Shares in the capital of the Company issued on the same terms and condition as the Company's existing Shares;

(e) the October Placement Shares were issued on 9 November 2026;

(f) the issue price of the October Placement Shares was $0.0022 each;

(g) the purpose of the issue of the October Placement Shares was to raise approximately $700,000 (before costs). Funds raised from the issue of the October Placement Shares will be used in the manner set out in Section 14.1 above;

(h) the October Placement Shares were not issued under an agreement; and

(i) a voting exclusion statement is set out in the Notice in respect of Resolutions 11(a) and 11(b).

14.5 Board recommendation

The Directors of the Company believe Resolutions 11(a) and 11(b) are in the best interest of the Company and its Shareholders and unanimously recommend that the Shareholders vote in favour of Resolutions 11(a) and 11(b). The Chair intends to vote all undirected proxies in favour of Resolutions 11(a) and 11(b).

15. RESOLUTION 12 – RATIFICATION OF PRIOR ISSUE OF OCTOBER LEAD MANAGER SHARES IN LIEU OF FEES

15.1 General

As set out in Section 14.1, Pheonix Global Investments Pty Ltd acted as lead manager to the October Placement pursuant to the October Lead Manager Mandate. A summary of the material terms of the October Lead Manager Mandate is set out below:

(a) **(Services):** the October Lead Manager agrees to provide lead manager services to the Company in respect of the October Placement.

(b) **(Fees):** as consideration for the Services, the Company has agreed to pay the October Lead Manager a capital raising fee of 6% (plus GST) of the gross proceeds of the October Placement. The Company may elect to pay the Fees in cash or through the issue of that number of fully paid ordinary shares equal to the value of the Fees, at a deemed issue price equal to the October Placement Shares (being $0.0022) (**October Lead Manager Shares**), together with one (1) Option on the same terms as the October Placement Options for every one (1) October Lead Manager Share issued (**October Lead Manager Options**). The issue of the October Lead Manager Shares will be pursuant to the Company's ASX Listing Rule 7.1 capacity, while the issue of the October Lead Manager Options will be subject to Shareholder approval.

For personal use only

The October Lead Manager Mandate is otherwise on terms and conditions that are considered standard for an agreement of this nature.

The Company issued the October Lead Manager Shares on 9 November 2026.

Resolution 12 seeks Shareholder approval for the ratification of the issue of the October Lead Manager Shares under and for the purpose of Listing Rule 7.4.

15.2 Listing Rules 7.1 and 7.4

A summary of Listing Rules 7.1 and 7.4 is set out above in Section 14.2.

The issue of the October Lead Manager Shares does not fit within the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 15% limit in Listing Rule 7.1, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rule 7.1 for the 12 month period following the date of issue of the October Lead Manager Shares.

The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval for such issues under Listing Rule 7.1. To this end, Resolution 12 seeks Shareholder approval for the ratification of the issue of the October Lead Manager Shares under and for the purpose of Listing Rule 7.4.

15.3 Technical information required by Listing Rule 14.1A

If Resolution 12 is passed, the issue of the October Lead Manager Shares will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date.

If Resolution 12 is not passed, the October Lead Manager Shares will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date.

15.4 Technical information required by Listing Rule 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided in relation to Resolution 12:

(a) the October Placement Shares were issued to Pheonix Global Investments Pty Ltd, being the October Lead Manager;

(b) a total of 19,090,909 October Lead Manager Shares were issued;

(c) the October Lead Manager Shares issued were all fully paid ordinary Shares in the capital of the Company issued on the same terms and condition as the Company's existing Shares;

(d) the October Lead Manager Shares were issued on 9 November 2026;

(e) the October Lead Manager Shares were issued at a deemed issue price of $0.0022 each, being the same issue price as the October Placement Shares;

(f) the purpose of the issue of the October Lead Manager Shares was to satisfy the Company's obligation to pay the Fees, while preserving the Company's cash reserves;

For personal use only

(g) the October Lead Manager Shares were issued under the October Lead Manager Mandate. A summary of the material terms of the October Lead Manager Madate is set out in Section 15.1; and

(h) a voting exclusion statement is set out in the Notice in respect of Resolution 12.

15.5 Board recommendation

The Directors of the Company believe Resolution 12 is in the best interest of the Company and its Shareholders and unanimously recommend that the Shareholders vote in favour of Resolution 12. The Chair intends to vote all undirected proxies in favour of Resolution 12.

16. RESOLUTION 13 – APPROVAL TO ISSUE OCTOBER PLACEMENT OPTIONS

16.1 General

As set out in Section 14.1, the issue of the October Placement Options is subject to Shareholder approval.

Accordingly, Resolution 13 seeks Shareholder approval pursuant to Listing Rule 7.1 for the issue of 318,181,818 October Placement Options to the October Placement Participants.

16.2 Listing Rule 7.1

A summary of Listing Rule 7.1 is set out above in Section 14.2.

The effect of Resolution 13 will be to allow the Company to issue the October Placement Options to the October Placement Participants during the period of 3 months after the Meeting (or longer period if allowed by ASX), without using the Company's 15% annual placement capacity.

16.3 Technical information required by Listing Rule 14.1A

If Resolution 13 is passed, the Company will be able to proceed with the issue of the October Placement Options. In addition, the issue of the October Placement Options will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date.

If Resolution 13 is not passed, the Company will not be able to proceed with the issue of the October Placement Options.

16.4 Technical information required by Listing Rule 7.3

Pursuant to and in accordance with Listing Rule 7.3, the following information is provided in relation to Resolution 13:

(a) the October Placement Options will be issued to the October Placement Participants, being sophisticated and professional investors who are clients of the October Lead Manager (and/or their respective nominees). The October Placement Participants were identified through a book build process, which involved the October Lead Manager seeking expressions of interest to participate in the October Placement from non-related parties of the Company;

(b) in accordance with paragraph 7.2 of Guidance Note 21, the Company confirms that none of the October Placement Participants are:

For personal use only

(i) related parties of the Company, members of the Company's Key Management Personnel, substantial holders of the Company, advisers of the Company or an associate of any of these parties; and

(ii) were issued more than 1% of the issued capital of the Company;

(c) up to 318,181,818 October Placement Options will be issued;

(d) the terms and conditions of the October Placement Options are set out in Schedule 2;

(e) the October Placement Options will be issued no later than three (3) months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the ASX Listing Rules);

(f) the October Placement Options will be issued for nil cash consideration;

(g) the purpose of the issue of the October Placement Options is as free-attaching Options to the October Placement Shares, and there are no funds will be raised from the issue of the October Placement Options;

(h) the October Placement Options are not being issued under an agreement;

(i) the October Placement Options are not being issued under, or to fund, a reverse takeover; and

(j) a voting exclusion statement is set out in the Notice in respect of Resolution 13.

16.5 Board recommendation

The Directors of the Company believe Resolution 13 is in the best interest of the Company and its Shareholders and unanimously recommend that the Shareholders vote in favour of Resolution 13. The Chair intends to vote all undirected proxies in favour of Resolution 13.

17. RESOLUTION 14 – APPROVAL TO ISSUE OCTOBER LEAD MANAGER OPTIONS

17.1 General

As set out in Section 15.1, the issue of the October Lead Manager Options is subject to Shareholder approval.

Accordingly, Resolution 14 seeks Shareholder approval pursuant to Listing Rule 7.1 for the issue of 19,090,909 October Lead Manager Options to the October Lead Manager.

17.2 Listing Rule 7.1

A summary of Listing Rule 7.1 is set out above in Section 14.2.

The issue of the October Lead Manager Options falls within exception 17 of ASX Listing Rule 7.2, as the issue of the October Lead Manager Options is subject to the Company obtaining prior Shareholder approval. Exception 17 under ASX Listing Rule 7.2 provides that if the issue of any securities requires prior shareholder approval, then such issue is not counted towards the 15% limit in ASX Listing Rule 7.1.

Resolution 14 seeks Shareholder approval for the issue of the October Lead Manager Options under Listing Rule 7.1.

For personal use only

17.3 Technical information required by Listing Rule 14.1A

If Resolution 14 is passed, the Company will be able to proceed with the issue of the October Lead Manager Options. In addition, the issue of the October Lead Manager Options will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date.

If Resolution 14 is not passed, the Company will not be able to proceed with the issue of the October Lead Manager Options and the Company will have to pay the Fees in cash.

17.4 Technical information required by Listing Rule 7.3

Pursuant to and in accordance with Listing Rule 7.3, the following information is provided in relation to Resolution 14:

(a) the October Lead Manager Options will be issued to Pheonix Global Investments Pty Ltd, being the October Lead Manager;

(b) up to 19,090,909 October Lead Manager Options will be issued;

(c) the terms and conditions of the October Lead Manager Options are set out in Schedule 2, being the same terms as the October Placement Options;

(d) the October Lead Manager Options will be issued no later than three (3) months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the ASX Listing Rules);

(e) the October Lead Manager Options will be issued for nil cash consideration;

(f) the purpose of the issue of the October Lead Manager Options is as free-attaching Options to the October Lead Manager Shares, in satisfaction of the Company's obligations to pay the Fees, and there are no funds will be raised from the issue of the October Lead Manager Options;

(g) the October Lead Manager Options will be issued under the October Lead Manager Mandate. A summary of the material terms of the October Lead Manager Madate is set out in Section 15.1;

(h) the October Lead Manager Options are not being issued under, or to fund, a reverse takeover; and

(i) a voting exclusion statement is set out in the Notice in respect of Resolution 14.

17.5 Board recommendation

The Directors of the Company believe Resolution 14 is in the best interest of the Company and its Shareholders and unanimously recommend that the Shareholders vote in favour of Resolution 14. The Chair intends to vote all undirected proxies in favour of Resolution 14.

For personal use only

Schedule 1 – Definitions

Schedule 1 of the Notice is supplemented by including the following defined term:

Addendum means this addendum to the Notice.

Additional Resolutions means Resolutions 11(a), 11(b), 12, 13 and 14 as set out in this Addendum.

Fees has the meaning given in Section 15.1.

October Lead Manager has the meaning given in Section 14.1.

October Lead Manager Mandate has the meaning given in Section 14.1.

October Lead Manager Options has the meaning given in Section 15.1.

October Lead Manager Shares has the meaning given in Section 15.1.

October Placement has the meaning given in Section 14.1.

October Placement Options has the meaning given in Section 14.1.

October Placement Participants has the meaning given in Section 14.4.

October Placement Shares has the meaning given in Section 14.1.

Replacement Proxy Form means the replacement proxy form annexed to this Addendum.

For personal use only

Schedule 2 – Terms and Conditions of October Placement Options and October Lead Manager Options

(a) **Entitlement**

Each Option entitles the holder to subscribe for one (1) Share upon exercise of the Option.

(b) **Exercise Price**

Subject to paragraph (i), the amount payable upon exercise of each Option is $0.004 (**Exercise Price**).

(c) **Expiry Date**

Each Option will expire at 5:00 pm (AWST), on the date that is three (3) years from the date of issue. An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.

(d) **Exercise Period**

The Options are exercisable at any time on or prior to the Expiry Date (**Exercise Period**).

(e) **Notice of Exercise**

The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate (**Notice of Exercise**) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.

(f) **Exercise Date**

A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (**Exercise Date**).

(g) **Timing of issue of Shares on exercise**

Following the Exercise Date and within the time period specified by the ASX Listing Rules, the Company will:

(i) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Notice of Exercise and for which cleared funds have been received by the Company;

(ii) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and

(iii) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options.

If a notice delivered under (g)(ii) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things

For personal use only

necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.

(h) **Shares issued on exercise**

Shares issued on exercise of the Options rank equally with the then issued shares of the Company.

(i) **Reconstruction of capital**

If at any time the issued capital of the Company is reconstructed, all rights of a holder are to be changed in a manner consistent with the Corporations Act and the ASX Listing Rules at the time of the reconstruction.

(j) **Participation in new issues**

There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.

(k) **Transferability**

The Options are transferable subject to any restriction or escrow arrangements imposed by ASX or under applicable Australian securities laws.

(l) **Change in Exercise Price**

An Option does not confer the right to a change in Exercise Price or a change in the number of underlying securities over which the Option can be exercised.

For personal use only

Schedule 3 – Issues of Equity Securities Since 28 November 2025 Under Rule 7.1A

Date	Description	Quantity	Class	Recipients	Issue price and discount to Market Price	Form of consideration
9/11/2026	Shares issued under a placement using available capacity under both Listing Rule 7.1 and 7.1A.	258,360,727 Shares issued under Listing Rule 7.1A.	Shares	Sophisticated and professional investors who are existing clients of the lead manager or other participating brokers of the placement.	The issue price of Shares issued under the Placement was $0.0022. The issue price represents a 10% premium to the COmpany's closing price of $0.002 on 22 October 2026, and a 24.14% discount to the 15-day VWAP of $0.0029.	Cash Amount Raised – $568,393.60 Amount Spent - $nil Amount remaining - $568,393.60 Intended use for remaining amount – strengthen balance sheet and additional working capital to support the advancement and commercialisation of the Company's existing programs.

personal use only

skin elements
enhancing health + wellness naturally

ACN 608 047 794

LODGE YOUR VOTE

ONLINE
https://au.investorcentre.mpms.mufg.com

BY MAIL
Skin Elements Limited
C/- MUFG Corporate Markets (AU) Limited
Locked Bag A14
Sydney South NSW 1235 Australia

BY FAX
+61 2 9287 0309

BY HAND*
MUFG Corporate Markets (AU) Limited
Parramatta Square, Level 22, Tower 6,
10 Darcy Street, Parramatta NSW 2150

*During business hours Monday to Friday

ALL ENQUIRIES TO
Telephone: 1300 554 474 Overseas: +61 1300 554 474

For personal use only

REPLACEMENT PROXY FORM

This is a **replacement Proxy Form** to the form sent out on **Thursday, 29 October 2026**.

LODGEMENT OF A PROXY FORM

This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given above by **12:00pm (AWST) on Saturday, 28 November 2026,** being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting.

Proxy Forms may be lodged using the reply paid envelope or:

ONLINE
https://au.investorcentre.mpms.mufg.com

Login to the Investor Centre website using the holding details as shown on the Voting Form. Select 'Voting' and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their "Holder Identifier" - Securityholder Reference Number (SRN) or Holder Identification Number (HIN).

BY MOBILE DEVICE

Our voting website is designed specifically for voting online. You can now lodge your vote by scanning the QR code adjacent or enter the voting link **https://au.investorcentre.mpms.mufg.com** into your mobile device. Log in using the Holder Identifier and postcode for your shareholding.

To scan the code you will need a QR code reader application which can be downloaded for free on your mobile device.

QR Code

HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM

YOUR NAME AND ADDRESS

This is your name and address as it appears on the Company's share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. **Please note: you cannot change ownership of your shares using this form.**

APPOINTMENT OF PROXY

If you wish to appoint the Chairman of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chairman of the Meeting as your proxy, please write the name of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company.

DEFAULT TO CHAIRMAN OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chairman of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chairman of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Resolution is connected directly or indirectly with the remuneration of KMP.

VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT

You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as they choose. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF A SECOND PROXY

You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company's share registry or you may copy this form and return them both together.

To appoint a second proxy you must:

(a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and

(b) return both forms together.

SIGNING INSTRUCTIONS

You must sign this form as follows in the spaces provided:

Individual: where the holding is in one name, the holder must sign.

Joint Holding: where the holding is in more than one name, either shareholder may sign.

Power of Attorney: to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the *Corporations Act 2001*) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate "Certificate of Appointment of Corporate Representative" must be received at support@cm.mpms.mufg.com prior to admission in accordance with the Notice of Annual General Meeting. A form of the certificate may be obtained from the Company's share registry or online at www.mpms.mufg.com/en/mufg-corporate-markets.

IF YOU WOULD LIKE TO ATTEND AND VOTE AT THE ANNUAL GENERAL MEETING, PLEASE BRING THIS FORM WITH YOU. THIS WILL ASSIST IN REGISTERING YOUR ATTENDANCE.

NAME SURNAME
ADDRESS LINE 1
ADDRESS LINE 2
ADDRESS LINE 3
ADDRESS LINE 4
ADDRESS LINE 5
ADDRESS LINE 6

X99999999999

For personal use only

REPLACEMENT PROXY FORM

This is a **replacement Proxy Form** to the form sent out on **Thursday, 29 October 2026.**

I/We being a member(s) of Skin Elements Limited and entitled to attend and vote hereby appoint:

STEP 1 APPOINT A PROXY

☐ the Chairman of the Meeting *(mark box)*

OR if you are **NOT** appointing the Chairman of the Meeting as your proxy, please write the name of the person or body corporate you are appointing as your proxy

or failing the person or body corporate named, or if no person or body corporate is named, the Chairman of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the 2026 Annual General Meeting of the Company to be held at **12:00pm (AWST) on Monday, 30 November 2026 at Boorloo Meeting Room, 108 St Georges Terrace, Perth, Western Australia** (the **Meeting**) and at any postponement or adjournment of the Meeting.

Important for Resolution 1: If the Chairman of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chairman of the Meeting to exercise the proxy in respect of Resolution 1, even though the Resolution is connected directly or indirectly with the remuneration of a member of the Company's Key Management Personnel (**KMP**).

The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business.

STEP 2 VOTING DIRECTIONS

Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting.

Please read the voting instructions overleaf before marking any boxes with an ☒

Resolutions

		For	Against	Abstain*
1	Adoption Of Remuneration Report (Non-Binding Resolution)	☐	☐	☐
2	Election Of Director – Mr Joshua Gordon	☐	☐	☐
3	Election Of Director – Mr Rod Nicholas	☐	☐	☐
4	Re-Election Of Director – Mr Harry Spindler	☐	☐	☐
5	Ratification Of Prior Issue Of The June Placement Shares	☐	☐	☐
6	Ratification Of Prior Issue Of The Lead Manager Shares In Lieu Of Fees	☐	☐	☐
7	Ratification Of Prior Issue Of The Consultancy Shares	☐	☐	☐
8	Ratification Of Prior Issue Of Shares To Mandate Corporate	☐	☐	☐
9	Ratification Of Prior Issue Of Shares To Ahamed Rizvi Wahid	☐	☐	☐
10	Approval Of 10% Placement Facility	☐	☐	☐
11(A)	Ratification Of Prior Issue Of 59,821,091 October Placement Shares Issued Under The Company's Listing Rule 7.1 Capacity	☐	☐	☐
11(B)	Ratification Of Prior Issue Of 258,360,727 October Placement Shares Issued Under The Company's Listing Rule 7.1A Capacity	☐	☐	☐
12	Ratification Of Prior Issue Of October Lead Manager Shares In Lieu Of Fees	☐	☐	☐
13	Approval To Issue October Placement Options	☐	☐	☐
14	Approval To Issue October Lead Manager Options	☐	☐	☐

ⓘ * If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your votes will not be counted in computing the required majority on a poll.

STEP 3 SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED

Shareholder 1 (Individual)	Joint Shareholder 2 (Individual)	Joint Shareholder 3 (Individual)
Sole Director and Sole Company Secretary	Director/Company Secretary (Delete one)	Director

This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder's attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company's constitution and the *Corporations Act 2001* (Cth).